NMN and Blood Pressure: What the 2026 Meta-Analysis Found

NMN blood pressure research now shows a measurable—but modest—human signal. A 2026 meta-analysis found a small average reduction in diastolic blood pressure, while the overall systolic effect was not significant. NMN is not an antihypertensive treatment.

What the 2026 blood-pressure meta-analysis found

The pooled diastolic effect was approximately −2.15 mmHg versus placebo. The overall systolic result was not statistically significant. In adults aged 60 or older, a subgroup analysis found a systolic reduction of about 3.94 mmHg. ^[1]

Subgroup analyses in small datasets are hypothesis-generating. This should not be translated into “NMN lowers blood pressure by 4 points” for every older adult.

Why NAD+ might affect vascular function

Vascular aging involves endothelial dysfunction, oxidative stress, smooth-muscle changes and inflammatory signaling. NAD-consuming enzymes such as CD38 can change with age and disease, providing a mechanistic reason to study NAD restoration.

Qiu and colleagues linked CD38-mediated NAD+ depletion with hypertension and vascular injury in mixed mechanistic work that included human NMN intervention data. ^[2]

Mechanism does not establish treatment efficacy.

Arterial stiffness

Katayoshi and colleagues examined NAD metabolism and arterial stiffness after longer-term NMN supplementation in a randomized double-blind placebo-controlled study. ^[3]

Arterial stiffness, systolic pressure and cardiovascular events are related but distinct outcomes. Improving one surrogate does not automatically prove fewer heart attacks or strokes.

What the broader 2026 meta-analysis says

The broader safety/metabolic meta-analysis found no significant pooled systolic blood-pressure effect and a small diastolic reduction. ^[4]

The consistency between two syntheses supports a modest DBP signal, but the effect size is far smaller than the marketing phrase “improves cardiovascular health” suggests.

Can NMN replace blood-pressure medicine?

No. Antihypertensive medications are supported by large clinical-outcome trials demonstrating reductions in stroke, heart failure and other events. NMN does not have comparable cardiovascular-outcome evidence.

Could NMN make blood pressure too low?

A major hypotension signal has not emerged from the randomized literature. Still, someone taking several antihypertensives or experiencing dizziness should treat any supplement-associated BP change as clinically relevant and monitor rather than assuming it is harmless.

How much NMN was used in BP studies?

The meta-analysis pooled multiple doses and durations rather than identifying one validated antihypertensive dose. ^[5] There is no evidence-based reason to escalate NMN specifically to lower blood pressure.

How strong is the blood-pressure evidence?

Current evidence supports a small pooled diastolic signal, but not NMN as an antihypertensive treatment. Blood pressure is a useful example of why an evidence hierarchy matters. The most current dedicated synthesis included 349 participants from 10 randomized trials with 11 intervention arms. The pooled diastolic result was statistically significant but modest: about −2.15 mmHg versus placebo. Systolic blood pressure fell by about −1.58 mmHg overall, but the confidence interval crossed zero. ^[6]

A separate 2026 systematic review using a random-effects model reached a very similar pattern: no significant overall systolic effect and a small diastolic reduction of about 2.43 mmHg. ^[7] When two independent syntheses point in the same direction, the diastolic signal becomes more credible. It still remains a small surrogate change rather than evidence of fewer strokes, heart attacks or heart-failure admissions.

Who was actually studied?

Most of the evidence comes from small, heterogeneous adult cohorts rather than dedicated hypertension trials. The phrase “NMN lowers blood pressure” sounds broader than the evidence. The pooled trials enrolled relatively small groups of adults across different ages, baseline metabolic states, countries, doses and treatment durations. In many of those studies, blood pressure was not the primary outcome. That matters because trials powered to detect a change in NAD+, walking performance or safety may not be large enough to answer a hypertension question reliably.

The dedicated 2026 meta-analysis also notes that most participants had elevated blood pressure rather than a formal diagnosis of established hypertension. ^[8] So we do not yet have the same evidence in people with stage 1 or stage 2 hypertension receiving contemporary multidrug treatment.

What happened in adults aged 60 and older?

One of the most discussed findings is the subgroup result in participants aged 60 and older: systolic pressure was lower by about 3.94 mmHg in the pooled estimate. ^[9]

This is biologically plausible because age-related vascular dysfunction and NAD metabolism are central to the NMN hypothesis. But subgroup analyses are more fragile than the main prespecified overall result. Multiple subgroup comparisons increase the chance of a seemingly positive result, and the number of participants contributing to each subgroup is smaller. The correct interpretation is an age-specific signal worth testing prospectively, not “NMN lowers systolic pressure by four points if you are over 60.”

Could NMN affect blood pressure through the endothelium?

The mechanistic case centers on endothelial cells, oxidative stress, nitric-oxide signaling and NAD-consuming enzymes. CD38 activity increases in several aging and inflammatory contexts and can contribute to NAD depletion. Qiu and colleagues linked CD38 upregulation, NAD exhaustion and vascular damage in hypertension and included a human NMN intervention component within a broader mechanistic study. ^[10]

Other NMN work has examined arterial stiffness alongside NAD metabolism. ^[11] These studies make the vascular hypothesis coherent. They do not show that raising NAD+ necessarily restores endothelial function enough to change cardiovascular events.

Why a statistically significant result can still be clinically modest

Statistical significance asks whether the observed difference is unlikely to be explained by random sampling under a specific model. Clinical significance asks whether the size of the change meaningfully alters symptoms or risk. The two are not interchangeable.

A roughly two-millimeter average diastolic change is scientifically interesting, especially when sensitivity analyses remain stable, but it is not comparable evidence to an antihypertensive therapy tested in thousands of people for hard cardiovascular outcomes. An evidence-based page should preserve that scale.

Does dose matter?

The current meta-analysis contains a range of doses, including multiple arms from higher-dose studies, but it did not identify one reproducible dose that acts as an antihypertensive. ^[12] This means a consumer should not interpret “higher dose” as “greater blood-pressure reduction.” Dose-response for NAD biomarkers and dose-response for blood pressure are different questions.

What should future NMN hypertension trials look like?

• Enroll people with clearly defined hypertension rather than treating blood pressure as a secondary measurement in otherwise unrelated trials.
• Use ambulatory or repeated standardized blood-pressure measurements to reduce noise and white-coat effects.
• Prespecify systolic and diastolic pressure as primary or key secondary outcomes.
• Stratify by age, baseline pressure and medication use before looking at subgroups.
• Run long enough to distinguish transient changes from durable effects.
• Report clinically relevant outcomes and medication changes, not only NAD biomarkers.

Where this leaves NMN for cardiovascular health

The cardiovascular case for NMN is more mature than “there is no human evidence,” but much less mature than “NMN protects the heart.” The most defensible claim in 2026 is that a small diastolic blood-pressure signal now appears across pooled randomized evidence, while systolic benefit remains uncertain outside exploratory older-adult subgroups.

For the broader distinction between a biomarker signal and a proven benefit, see our NMN benefits evidence map. For medication overlap, see NMN drug interactions.

Related NMN guides

• NMN benefits
• NMN with blood-pressure medication
• NMN human trials
• NMN and metabolic health

Bottom line

Blood pressure is one of the NMN outcomes where a modest pooled human signal now exists. The effect is interesting, not therapeutic proof. It supports further cardiovascular trials, not replacing antihypertensive treatment with a supplement.